Completed PHASE2 INTERVENTIONAL 2-arm NCT00668642

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer

Sponsor: Endeavor Health

Conditions Prostate Cancer

Interventions Dutasteride Placebo

Updated 8 times since 2017 Last updated: Jul 26, 2023 Started: Mar 31, 2007 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00668642, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Endeavor Health, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Mar 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Sep 2023 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endeavor Health
Northwestern University
University of Chicago

Data source: Endeavor Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States
• Evanston, United States